Method for quantifying nicotinamide adenine dinucleotide (NAD +) or nicotinamide mononucleotide (NMN), and kit and filter paper for implementing method
By optimizing the composition and treatment methods of filter paper, combined with mass spectrometry analyzer and other technologies, the decomposition and storage stability problems of NAD+ and NMN quantification in DBS method are solved, and accurate quantities and high stability of NAD+ and NMN measurements are achieved.
Patent Information
- Application Number
- CN202280093946.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-23
- Filing Date
- 2022-08-24
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, when quantifying nicotinamide adenine dinucleotide (NAD+) and nicotinamide single nucleotide (NMN) using the dry blood plaque method (DBS method), there is a problem of poor decomposition and storage stability, which leads to failure. Accurate quantity.
By contacting the filter paper with a solvent, the filter paper is added with blood from the subject and contains free radical inhibitors or chaotropic agents, and quantified by combining with mass spectrometers and other methods, using surfactants such as sodium dodecyl sulfate and sulfur. guanidine cyanate filter paper, optimize the composition and treatment methods of filter paper to improve the accuracy and stability of quantification.
The accurate quantification of NAD+ or NMN is achieved, which improves its storage stability, ensures the reliability and accuracy of quantitative results, and is suitable for monitoring NAD+ levels in organisms.
Smart Images

Figure BDA0005052421880000041 
Figure BDA0005052421880000121 
Figure BDA0005052421880000131
Abstract
Description
Technical Field
[0001] The present invention relates to a method for quantifying nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN), and a kit and filter paper for implementing the method. Background Art
[0002] Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for energy production reactions. It has been reported that NAD+ decreases with aging in rodents, humans, and the like (Non-Patent Document 1).
[0003] On the other hand, nicotinamide mononucleotide (NMN) is also present in various biological species, and is a precursor of NAD+, which is collectively referred to as the vitamin B3 group, together with nicotinamide riboside (NR). In addition, it has been reported that for rodents, etc., these NAD+ precursors can improve the condition of aging-related diseases by increasing NAD+ in the body (Non-patent Document 2). In addition, in recent years, NAD+ precursors such as NMN have been sold as anti-aging nutrients, and the increase in NAD+ levels in the body has attracted much attention.
[0004] Therefore, it is expected that quantifying the levels of NAD+ precursors such as NAD+ and NMN in the body will help understand the disease and aging. Among them, various methods for quantifying the levels of NAD+ precursors such as NAD+ and NMN have been studied. For example, Non-Patent Document 3 reports that NAD+ can be detected by the Dried Blood Spot method (DBS method).
[0005] Here, the DBS method is a method in which the blood from the subject is dripped (also called spot) onto a dedicated filter paper and dried, and then the concentration of the substance to be measured in the blood is quantified by extraction. The DBS method has the following advantages: (1) Since the blood is used directly, there is no need to separate the plasma component from the blood; (2) Compared with the conventional blood test, it can be performed with a smaller amount of blood, so it can be collected by self-collection; (3) Since the filter paper is used, it is easy to transport to the inspection agency, etc. Therefore, it is actually used in the centralized physical examination of newborns, remote therapeutic drug monitoring (Therapeutic Drug Monitoring: TDM), etc., and it is a method that has attracted much attention.
[0006] Prior art literature
[0007] Non-patent literature
[0008] Non-patent literature 1: Experimental gerontology, 2020, 134, 110888
[0009] Non-patent document 2: Biochemistry, Vol. 87, No. 2, pp. 239-244, 2015
[0010] Non-patent document 3: Metabolites, 2017, 7, 35 Summary of the invention
[0011] Problems to be solved by the invention
[0012] However, for the above-mentioned NAD+, NMN and other NAD+ precursors, when you want to quantify them according to the DBS method described in non-patent document 3, there is a problem that you cannot accurately quantify them. This is because: first, the degree of decomposition of NAD+, NMN and other NAD+ precursors tends to change significantly due to their storage state, and when you want to quantify them, you need to do special treatments such as quick freezing in advance. In addition, the DBS method described in non-patent document 3 sometimes has poor stability such as storage stability after the filter paper is added due to the difference in the quantitative object, so it cannot be accurately quantified.
[0013] An object of the present invention is to provide a method for accurately quantifying NAD+ or NMN or other NAD+ precursors using the DBS method.
[0014] Means used to solve problems
[0015] The present invention has been made to solve the above-mentioned problems, and includes the following configurations.
[0016] [1] A method for quantifying nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN) as a test subject, comprising the following steps 1 and 2:
[0017] (Step 1) a step of bringing filter paper to which the blood from the subject is added and which is impregnated with a free radical inhibitor or a chaotropic agent into contact with a solvent; and
[0018] (Step 2) A step 2 of quantifying the nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN) in the solvent obtained in the step 1.
[0019] [2] The method according to [1], which is a method for quantifying nicotinamide adenine dinucleotide (NAD+).
[0020] [3] The method according to [1] or [2], wherein the filter paper is impregnated with a chaotropic agent.
[0021] [4] The method according to [1] or [2], wherein the free radical inhibitor contains a surfactant.
[0022] [5] The method according to [4], wherein the surfactant is an anionic surfactant.
[0023] [6] The method according to [5], wherein the anionic surfactant is sodium dodecyl sulfate.
[0024] [7] The method according to [3], wherein the chaotropic agent comprises a guanidine salt.
[0025] [8] The method according to [7], wherein the guanidine salt is guanidine thiocyanate.
[0026] [9] The method according to any one of [1] to [8], wherein the filter paper is made of cellulose.
[0027]
[10] The method according to any one of [1] to [9], wherein the solvent is water and / or acetonitrile.
[0028]
[11] The method according to
[10] , wherein the solvent is water.
[0029]
[12] The method according to any one of [1] to
[11] , wherein the quantification in the step 2 is performed by a method using a mass spectrometer or a colorimetric method.
[0030]
[13] A kit for carrying out the method according to any one of [1] to
[12] , comprising a blood collection device and filter paper impregnated with a free radical inhibitor or a chaotropic agent.
[0031]
[14] Filter paper used for implementing the method according to any one of [1] to
[12] , and impregnated with a free radical inhibitor or a chaotropic agent.
[0032] Effects of the Invention
[0033] According to the present invention, since NAD+ precursors such as NAD+ and NMN have good storage stability, a method for accurately quantifying NAD+ precursors such as NAD+ and NMN using the DBS method can be provided. DETAILED DESCRIPTION
[0034] <Method for Quantifying Nicotinamide Adenine Dinucleotide (NAD+) or Nicotinamide Mononucleotide (NMN)>
[0035] The method of the present invention for quantifying nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN) (hereinafter sometimes referred to as the quantitative method of the present invention) includes: step 1 (hereinafter sometimes referred to as step 1 of the present invention) of contacting filter paper with a solvent, wherein the filter paper is added with blood from a subject and is impregnated with a free radical inhibitor or a chaotropic agent; and step 2 (hereinafter sometimes referred to as step 2 of the present invention) of quantifying the NAD+ or NMN in the solvent obtained by the aforementioned step 1.
[0036] The quantitative determination method of the present invention will be described in detail below.
[0037] [Nicotinamide adenine dinucleotide (NAD+)]
[0038] Nicotinamide adenine dinucleotide (NAD+) in the quantitative method of the present invention is a coenzyme essential for energy production reaction as described above, and is also known as an electron transport system in all eukaryotic organisms, archaea, fungi, and the like.
[0039] In addition, nicotinamide adenine dinucleotide can present both oxidized and reduced forms in vivo, and in the present invention, it means oxidized nicotinamide adenine dinucleotide (i.e., NAD+). In addition, the old names of NAD+ such as diphosphate pyridine nucleotide, coenzyme I, coenzyme I, and CO dehydrogenase I are also included in the nicotinamide adenine dinucleotide in the present invention.
[0040] [Nicotinamide mononucleotide (NMN)]
[0041] As described above, nicotinamide mononucleotide (NMN) in the quantitative method of the present invention refers to NAD+ precursors that exist in various biological species and are collectively referred to as vitamin B3 group. In addition, NMN is also known to have various functions such as activation of mitochondria and activation of Sirtuin genes, which are so-called longevity genes.
[0042] In addition, the structure of NMN is shown below.
[0043] [Chemistry 1]
[0044]
[0045] As described above, the quantification target substance in the quantification method of the present invention is NAD+ and / or NMN, and according to the quantification method of the present invention, they can be accurately quantified. Among them, from the perspective of quantitative accuracy, the quantification target substance in the quantification method of the present invention is more preferably NAD+.
[0046] It goes without saying that the above-mentioned "quantification" in the present invention is the calculation of the concentration, mass, molar amount, etc. of NAD+ or NMN in the blood from the subject described later.
[0047] [Subjects]
[0048] As the subject in the quantitative method of the present invention, mammals such as humans, monkeys, mice, rats, dogs, cats, pigs, rabbits, etc. can be listed, preferably humans, monkeys, mice or rats, and more preferably humans. In addition, as the human, for example, healthy people, patients suffering from diseases related to the increase or decrease of NAD+ and / or NMN, and people suspected of suffering from diseases related to the increase or decrease of NAD+ and / or NMN can be listed. As the disease, specifically, for example, aging diseases can be listed.
[0049] [Process 1]
[0050] Step 1 of the present invention is a step of bringing filter paper, to which blood from a subject is added and impregnated with a free radical inhibitor or a chaotropic agent, into contact with a solvent. Step 1 is described in detail below.
[0051] The blood in step 1 of the present invention refers to blood from the above-mentioned subject, and specific examples thereof include whole blood, blood cells, plasma, and serum. Among these, whole blood is preferred.
[0052] In addition, as a method for collecting blood from the subject, it is usually sufficient to perform the method according to the art, and examples thereof include methods based on a self-blood collection device, etc. Examples of the self-blood collection device include, for example, an MBS micro-blood collection kit (Microblood Science Co., Ltd.). When the subject is a human, for example, blood can be collected from the fingertips of the human's hands or feet using the self-blood collection device.
[0053] The filter paper in step 1 of the present invention is the one to which the blood from the subject is added, and is impregnated with a free radical inhibitor or a chaotropic agent. Among them, from the viewpoint of quantitative accuracy, it is more preferable to impregnate with a chaotropic agent.
[0054] The free radical inhibitor is a substance that destroys protein-protein interactions and denatures proteins, and specifically includes, for example, surfactants, buffers, and the like.
[0055] As the surfactant, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, etc. can be listed, among which anionic surfactants are preferred. As the anionic surfactant, sodium dodecyl sulfate (sometimes also referred to as sodium lauryl sulfate), lithium dodecyl sulfate, sodium cholate, sodium deoxycholate, etc. can be listed, among which sodium dodecyl sulfate is preferred.
[0056] Examples of the buffer include TRIS buffers such as tris(hydroxymethyl)aminomethane buffer, phosphate buffer, citrate buffer, glycine buffer, 3-morpholinopropanesulfonic acid buffer, acetate buffer, barbiturate buffer, borate buffer, and Gould's buffer such as carbonate buffer. Among these, TRIS buffer is preferred.
[0057] The chaotropic agent is a substance that reduces the interaction between water molecules and thereby destabilizes the structure of proteins, and contains at least a guanidine salt.
[0058] Examples of the guanidine salt include guanidine thiocyanate, guanidine hydrochloride, guanidine nitrate, and guanidine sulfate. Among these, guanidine thiocyanate is preferred.
[0059] As a method for impregnating the above-mentioned free radical inhibitor and chaotropic agent into filter paper, any method commonly performed in the art may be used, and examples thereof include a vacuum impregnation method in which the filter paper is immersed in a solution containing the free radical inhibitor or chaotropic agent for a predetermined time, a vacuum pressure impregnation method, a method in which the free radical inhibitor or chaotropic agent is directly coated or covered on the filter paper, and the like.
[0060] As the main component (matrix) of the filter paper in the process 1 of the present invention, cellulose, cotton, pulp, etc. can be listed, among which cellulose is preferably used. As a method for obtaining the filter paper of the cellulose matrix, any method generally used in the art can be used. As the method, for example, the following method is used: water is mixed with cellulose, and after the mixed solution is dried by a paper machine, water is removed from the mixed solution, and an automatic filter paper punching machine is used to manufacture the filter paper. In addition, the method described in the Japanese Special Fair 08-032995 Gazette, etc. can also be referred to.
[0061] The thickness of the filter paper in step 1 of the present invention may be in the range of 500 μm to 800 μm, and is preferably in the range of 550 μm to 750 μm.
[0062] The weight of the filter paper in step 1 of the present invention may be, for example, a weight per unit area (mg / cm 2 ) is 5mg / cm 2 ~50mg / cm 2 That is, preferably 15 mg / cm 2~35mg / cm 2 .
[0063] In particular, when the filter paper in step 1 of the present invention is impregnated with a free radical inhibitor, the weight of the filter paper, for example, the weight per unit area (mg / cm 2 ) is 5mg / cm 2 ~50mg / cm 2 That is, preferably 15 mg / cm 2 ~20mg / cm 2 In addition, when the filter paper in step 1 of the present invention is impregnated with a chaotropic agent, the weight of the filter paper may be, for example, a weight per unit area (mg / cm 2 ) is 5mg / cm 2 ~50mg / cm 2 That is, preferably 30mg / cm 2 ~35mg / cm 2 .
[0064] In addition, when measuring the weight per unit area, for example, a Saluterius electronic balance (MSA225S-100-DI) can be used.
[0065] In addition, other parameters such as the length in length and breadth of the filter paper in the operation 1 of the present invention, shape, the impregnation concentration of the above-mentioned free radical inhibitor and the chaotropic agent can be set arbitrarily considering the conditions of actual use. Especially, as this shape, it is not particularly limited, and for example, a circle, a quadrilateral, etc. can be listed.
[0066] The filter paper used in step 1 of the present invention may have the above-mentioned properties. Examples of filter papers satisfying the above-mentioned properties include Whatman FTA DMPK-A Card (GE Healthcare), QIAcard FTA DMPK-ACard (QIAGEN), Whatman FTA DMPK-B Card (GE Healthcare), and QIAcard FTA DMPK-B Card (QIAGEN). Therefore, these can be used.
[0067] In addition, regarding the above-mentioned Whatman FTA DMPK-A Card (GE Healthcare) and QIAcard FTA DMPK-A Card (QIAGEN), as described in the examples below, they are impregnated with a free radical inhibitor (sodium dodecyl sulfate), and the main component of the filter paper is cellulose. In addition, regarding the above-mentioned Whatman FTA DMPK-B Card (GE Healthcare) and QIAcard FTA DMPK-B Card (QIAGEN), as described in the examples below, they are impregnated with a chaotropic agent (guanidine thiocyanate), and the main component of the filter paper is cellulose.
[0068] The solvent in step 1 of the present invention refers to a solvent used to extract components containing NAD+ and NMN from filter paper to which blood from a subject is added. Specifically, examples include water, acetonitrile, a mixture of water and acetonitrile, alcohols such as ethanol, etc. Among these, water or a mixture of water and acetonitrile is preferred, and water is more preferred. As the water, ion exchange water, deionized water, pure water, ultrapure water, distilled water, etc. can be listed, among which ultrapure water is preferred. In addition, when using a mixture of water and acetonitrile, as the ratio of the two, it is sufficient to be in the range of 80% water: 20% acetonitrile to 20% water: 80% acetonitrile, preferably in the range of 80% water: 20% acetonitrile to 40% water: 60% acetonitrile.
[0069] When preparing the above-mentioned solvent, an internal standard substance corresponding to the quantification target substance may be added to the solvent.
[0070] In step 1 of the present invention, the method for contacting the filter paper with the solvent can be any method commonly used in the art, and specifically, a method of adding a solvent in an amount sufficient to immerse the filter paper and mixing the solvent can be cited. The amount is, for example, 100 μL to 1000 μL, and can be appropriately adjusted according to the conditions of the filter paper, the performance of the equipment used for quantitative determination described later, and the like.
[0071] As said method, more specifically, for example, as long as as follows. First, take the blood from this subject of prescribed amount from the subject in advance, add 1 μ L~10 μ L of this blood to the prescribed position of filter paper in advance. Thereafter, cut the position with blood added in the filter paper, and administer to tubes such as 2mL tubes. Then, carry out by adding 100 μ L~1000 μ L of above-mentioned solvent in this tube. After adding solvent, stirrers such as micro stirrer can be utilized to mix prescribed time (about 10 minutes~60 minutes) at room temperature as needed.
[0072] In addition, when implementing the above method, reference may be made to non-patent literature 1, non-patent literature 3, Japanese Patent Publication No. 2015-508493, Japanese Patent Publication No. 2018-530766, Japanese Patent Publication No. 2014-503197, Japanese Patent Publication No. 2011-506922, Japanese Patent Publication No. 2004-505277, "Uniformity of Drying Matrik Spot (Uniformity of Drying Matrix Point Addition)", application notes (Agilent Technologies), etc., as needed.
[0073] In this way, by carrying out step 1 of the present invention, the filter paper to which the blood from the subject has been added is brought into contact with the solvent, thereby making it possible to extract components including NAD+ and NMN from the filter paper to which the blood from the subject has been added.
[0074] In addition, after implementing the process 1 of the present invention and before implementing the process 2 of the present invention described later, in order to stabilize the quantitative object substance in the solvent obtained by the process 1 of the present invention, a process of adding a predetermined amount of an organic solvent can be implemented. As the organic solvent, acetonitrile, methanol, and ethanol can be listed, among which acetonitrile is preferably used. In addition, as the addition amount of the organic solvent, for example, with respect to the solvent 1 in the process 1 of the present invention, as long as 2 times the amount is added.
[0075] [Process 2]
[0076] Step 2 of the present invention is a step of quantifying NAD+ or NMN in the solvent obtained by step 1 of the present invention. Hereinafter, step 2 will be described in detail.
[0077] The method for quantifying NAD+ or NMN in step 2 described in the present invention refers to a method for quantifying NAD+ or NMN present in the solvent obtained by the operation of step 1 described in the present invention. It can be any method commonly performed in the art, and examples thereof include methods using a mass spectrometer, colorimetric methods, fluorescence methods, and the like.
[0078] As the method using a mass spectrometer, methods using a liquid chromatography mass spectrometer (LC-MS / MS), a gas chromatography mass spectrometer (GC / MS), a capillary electrophoresis mass spectrometer (CE / MS), etc. can be cited. Among these methods, specifically, for example, a separation unit having a chromatogram such as a liquid chromatography is used to separate the components in a biological sample (blood, etc.), and the various separated components are ionized in a mass analysis unit, and then, each mass-to-charge ratio (m / z) is separated, and this is performed. For a more specific method, it is sufficient to refer to the instructions attached to the machine, such as the methods described in WO2014 / 038524, WO2017 / 19588, WO2018 / 034346, etc.
[0079] The colorimetric method is a method of quantitatively measuring a target substance using an enzyme reader such as a microplate spectrophotometer based on the degree of color development when a biological sample (blood, etc.) reacts with a color developing agent.
[0080] As the developer, any developer commonly used in the art may be used, and specifically, for example, o-cresolphthalein complexone (OCPC), azo-III, chlorophosphine-III, eriochrome black T, glyoxal bis(o-aminophenol), NN (2-hydroxy-1-(2-hydroxy-4'-sulfo-1'-naphthylazo)-3-naphthoic acid), hydroxynaphthol blue, etc. In addition, the specific method of the above-mentioned colorimetry may be carried out according to the method commonly carried out in the art, and for example, Japanese Patent Application Laid-Open No. 2003-262629 may be referred to for carrying out.
[0081] When the quantification is performed by the colorimetric method, a commercially available kit or the like can be used. Specific examples of the kit include NAD / NADH Assay Kit-WST (Dojin Chemical Laboratories Co., Ltd.) and NAD+ / NADHAssay Kit (Colorimetric) (CELL BIOLABS).
[0082] The fluorescence method refers to a method of irradiating a biological sample (blood, etc.) containing a target substance with light and detecting the light generated when the sample is restored to a base state after being excited. Specifically, the method of quantifying the target substance using an enzyme reader such as a fluorescence microplate reader according to the degree of light generated when the excited electrons are restored to a base state. In addition, the specific method of the fluorescence method can be generally performed according to the method performed in the art, and it can be performed by referring to, for example, Japanese Patent Application Laid-Open No. 2012-202742, Japanese Patent Application Laid-Open No. 2009-276162, etc.
[0083] When the quantification is performed by the above-mentioned fluorescence method, a commercially available kit or the like can be used. Specific examples of the kit include NAD+ / NADH Assay Kit (Fluorometric) (CELL BIOLABS).
[0084] <Kit for implementing the method for quantifying NAD+ or NMN>
[0085] The kit for implementing the method for quantifying NAD+ or NMN of the present invention (hereinafter sometimes abbreviated as the kit of the present invention) comprises a blood collection device and filter paper impregnated with a free radical inhibitor or a chaotropic agent.
[0086] The kit of the present invention will be described in detail below.
[0087] As the blood sampling instrument, the same instrument as that for collecting blood from a subject is used, and the same specific examples, preferred examples, and the like are also described in the <Quantitative determination method of the present invention>.
[0088] The filter paper is impregnated with a radical inhibitor or a chaotropic agent, as described in the section "Quantitative determination method of the present invention", and the same applies to specific examples, preferred examples, and the like.
[0089] The kit of the present invention comprises at least the above-mentioned blood collection device and filter paper impregnated with a free radical inhibitor or a chaotropic agent, and may also comprise instructions, a container for storing the filter paper, and the like as necessary.
[0090] The specification substantially describes the principle and operation procedure of the quantitative method of the present invention using text, drawings, etc., and may be in the form of an operation manual, an attachment, a pamphlet, a leaflet, etc.
[0091] As the container, as long as it can store the filter paper, it is preferably capable of absorbing moisture. As such a container, specifically, for example, a hygroscopic standard bag can be listed. As the hygroscopic standard bag, specifically, for example, hygroscopic Kun (Maruto Industry Co., Ltd.) (registered trademark) can be listed.
[0092] According to the kit of the present invention, the quantitative method of the present invention can be carried out more simply, in a short time and accurately. In addition, according to the kit of the present invention, the subject (e.g., a person) can prepare filter paper added with blood from the subject at a specific place such as his own home, and mail the filter paper to an institution (e.g., an inspection institution, a medical institution, etc. having a mass spectrometer such as LC-MS / MS), where NAD+ and NMN are quantified. In short, an integrated service that feeds back the quantitative results to the subject can be provided. As described above and in the embodiments described below, the filter paper contained in the kit of the present invention has excellent storage stability of NAD+ and NMN, and therefore, the kit of the present invention can also be fully used in the above-mentioned services where filter paper mailing occurs.
[0093] <Application of the quantitative method of the present invention>
[0094] The quantitative method of the present invention described above also has the possibility of being applied in various fields. For example, as described above, age-related diseases are known as diseases related to the increase or decrease of NAD+ and NMN. Therefore, it is possible to consider using the correlation between the quantitative results obtained by the quantitative method of the present invention and the above-mentioned diseases to perform analysis (e.g., determination, diagnosis, etc.).
[0095] Example
[0096] Hereinafter, the present invention will be described in more detail with reference to Examples, but the scope of the present invention is not limited thereto.
[0097] <Example 1: Optimization study of extract>
[0098] The optimal solvent is explored for extracting components containing NAD+ and NMN from a specific filter paper to which blood from a subject has been added (i.e., it is equivalent to the solvent in step 1 described in the present invention. Hereinafter, it may be abbreviated as an extract).
[0099] In addition, if the intention of this Example 1 is supplemented, in this Example 1, the focus is on the optimization of the above-mentioned extract, so filter paper is not used. The specific method is as follows, but the following experimental system is presented: various candidate extracts are added to the blood, and the subsequent solution is directly used to quantify NAD+ and NMN by mass spectrometry.
[0100] [Experimental methods]
[0101] For 6-week-old male SD rats (3), laparotomy was performed under isoflurane inhalation anesthesia, and whole blood was collected from the abdominal aorta. 200 μL of the collected individual blood (i.e., whole blood) was dispensed into a 1.5 mL microtube and centrifuged (13200×g, 5 minutes, 4°C). The supernatant after centrifugation was removed, and the centrifugal residue was used as the blood cell fraction.
[0102] Thereafter, ultrapure water (Milli-Q integral 5 system / Merck Ltd.) and acetonitrile (Thermo Fisher Scientific) were mixed at ratios of 100:0, 80:20, 60:40, 40:60, 20:80, and 0:100 to prepare a total of 6 extracts.
[0103] Add 5 μL of individual blood or blood cells, 10 μL of a mixed aqueous solution of internal standard substances (NAD-d4 and NMN-d5 / TorontoResearch Chemicals, Inc.), and 295 μL of the extract to a 1.5 mL microtube, stir with a vortex stirrer, and mix at room temperature for 30 minutes using a micro stirrer (TOMY MICRO TUBE MIXERMT-400, stirring speed of 5). Take 100 μL of the mixed blood or blood cell extract solution into each microtube, add 200 μL of acetonitrile, stir with a vortex, and then centrifuge (24250 × g, 10 minutes, 4°C). Take 100 μL of the supernatant after centrifugation into a vial, add 0 μL to 50 μL of the internal standard substance mixed aqueous solution diluted according to the extract used in such a way that the final organic solvent content becomes 67%, and mix. Thereafter, NAD+ and NMN were measured separately by LC-MS / MS according to the following analysis conditions.
[0104] [LC-MS / MS measurement conditions]
[0105] [Table 1]
[0106]
[0107] [Table 2]
[0108]
[0109] [Table 3]
[0110]
[0111] [Experimental results]
[0112] The above experimental results are shown in Table 4.
[0113] [Table 4]
[0114]
[0115] It is clear from Table 4 that when using 6 kinds of extracts with different acetonitrile content ratios, the concentration of NAD+ and NMN in the blood is the highest when only water is used as the extract (i.e., water = 100% and acetonitrile content = 0%). In addition, when the acetonitrile content of the extract is adjusted to about 60%, compared with the case where the acetonitrile content is 0% (i.e., only water), although the concentration of NAD+ and NMN is lower, a certain degree of NAD+ and NMN concentration is confirmed.
[0116] However, it was found that when the acetonitrile content was adjusted to 80% or more, the concentrations of NAD+ and NMN decreased significantly. The tendency of the results was also the same when blood cells were used.
[0117] The results of Example 1 show that, in the quantification of NAD+ and NMN in the blood, water is the solvent that can most efficiently extract them from the blood.
[0118] If we examine this result, NAD+ and NMN, which are the objects of quantification, are present in blood cells. Therefore, it can be inferred that the blood cell components are destroyed by the osmotic pressure of water, thereby enabling them to be detected efficiently.
[0119] <Example 2: Study on Optimization of Filter Paper from the Perspective of Refrigerated Storage Stability>
[0120] For the filter paper to which the blood from the subject is added (i.e., the filter paper equivalent to the filter paper in step 1 described in the present invention), the optimal filter paper for quantifying NAD+ and NMN is explored when the filter paper to which the blood from the subject is added is refrigerated for a specified period of time.
[0121] The specific experimental method is as follows.
[0122] [Experimental methods]
[0123] By using the MBS micro-blood sampling test kit (Microblood Science Co., Ltd.), about 120 μL of blood (two containers of the recovery container of the kit) was collected from 5 subjects (adult men and women) for each test, and the blood was left on ice until the sample was processed. The subjects fasted in the morning of the sampling day, and the blood was collected at around 9 am. The test was carried out 4 times in total, and a total of 19 people were evaluated, excluding one person who was missing due to insufficient blood collection.
[0124] The collected blood was collected in 1.5 mL microtubes according to the subjects and mixed by gentle pipetting. 5 μL of blood was added (dropped / added) to multiple parts of 4 filter papers (Whatman FTA DMPK-A Card / GE healthcare, QIAcard FTA DMPK-BCard / QIAGEN, QIAcard FTA DMPK-C Card / QIAGEN, Whatman903protein saver card / Cytiva), sealed in a moisture absorption standard bag (Moisture absorption Kun (registered trademark) / Maruto Industry Co., Ltd.), and then refrigerated. Next, for the filter paper refrigerated after adding blood, after 2 days, 2 weeks (14 days or 15 days) or 1 month (30 days), the part with blood added was cut and recovered in a 2 mL microtube. 300 μL of aqueous solution mixed with internal standard substances (NAD-d4 and NMN-d4 / Toronto Research Chemicals, Inc.) was added, stirred with a vortex, and mixed at room temperature for 30 minutes using a micro stirrer (TOMY MICRO TUBE MIXER MT-400, stirring speed 5). 150 μL of the blood extraction solution was divided into micro tubes, 300 μL of acetonitrile was added, stirred with a vortex, and centrifuged (24250×g, 10 minutes, 4°C). 40 μL of the supernatant after centrifugation was divided into a vial and measured by LC-MS / MS.
[0125] On the other hand, as a sample for the initial value, 5 μL of blood was recovered in a 2 mL microtube (no filter paper was added), and 300 μL of an aqueous solution mixed with internal standard substances (NAD-d4 and NMN-d4 / Toronto Research Chemicals, Inc.) was added, stirred with a vortex, and mixed at room temperature for 30 minutes using a micro stirrer (TOMY MICRO TUBE MIXERMT-400, stirring speed of 5). 150 μL of the blood extraction solution was taken into each microtube, 300 μL of acetonitrile was added, and after stirring with a vortex, centrifugation was performed (24250×g, 10 minutes, 4°C). 40 μL of the supernatant after centrifugation was taken into a vial and measured by LC-MS / MS.
[0126] In addition, the Whatman FTA DMPK-A Card is sometimes referred to as DMPK-A card. The QIAcard FTA DMPK-B Card is sometimes referred to as DMPK-B card. The QIAcard FTA DMPK-C Card is sometimes referred to as DMPK-C card. In addition, the Whatman 903 protein saver card is sometimes referred to as 903 card.
[0127] [LC-MS / MS measurement conditions]
[0128] [Table 5]
[0129]
[0130] [Table 6]
[0131]
[0132] [Table 7]
[0133]
[0134] [Experimental results]
[0135] The above experimental results are shown in Tables 8 to 11.
[0136] [Table 8]
[0137]
[0138] [Table 9]
[0139]
[0140] [Table 10]
[0141]
[0142] [Table 11]
[0143]
[0144] As is clear from Tables 8 and 9 above, regarding NAD+, the concentrations of NAD+ after 2 days, 2 weeks, and 1 month of storage when using DMPK-A cards were 81.5%, 79.1%, and 71.8% of the initial value (0 day), respectively, showing good refrigerated storage stability. In addition, the concentrations of NAD+ after 2 days, 2 weeks, and 1 month of storage when using DMPK-B cards were 80.7%, 87.8%, and 79.8% of the initial value (0 day), respectively, showing better refrigerated storage stability than when using DMPK-A cards.
[0145] On the other hand, it is clear from Table 10 that the NAD+ concentrations after 2 days, 2 weeks and 1 month of storage when using DMPK-C card were 70.1%, 66.6% and 54.3% of the initial value (0 day), respectively, and it is clear from Table 11 that the NAD+ concentrations after 2 days, 2 weeks and 1 month of storage when using 903 card were 74.1%, 77.2% and 82.6% of the initial value (0 day), respectively. From these results, it can be seen that, regarding NAD+, when DMPK-A card and B card (especially DMPK-B card) are compared with DMPK-C card and 903 card, they are superior in terms of average refrigerated storage stability in each period.
[0146] In addition, regarding NMN, it is clear from Table 8 that the concentrations of NMN after 2 days, 2 weeks, and 1 month of storage when using the DMPK-A card were 73.1%, 80.6%, and 99.9% of the initial value (0 day), respectively, showing good refrigerated storage stability. In addition, it is clear from Table 9 that the concentrations of NMN after 2 days, 2 weeks, and 1 month of storage when using the DMPK-B card were 95.4%, 93.6%, and 78.6% of the initial value (0 day), respectively, which also showed good storage stability to the same degree as the DMPK-A card.
[0147] On the other hand, it is clear from Table 10 that the concentrations of NMN after 2 days, 2 weeks and 1 month of storage when using DMPK-C cards are 68.4%, 52.9% and NC of the initial value (0 day), respectively, and it is clear from Table 11 that the concentrations of NMN after 2 days, 2 weeks and 1 month of storage when using 903 cards are 60.1%, 64.5% and 56.3% of the initial value (0 day), respectively. From this result, it can be seen that regarding NMN, if DMPK-A cards and B cards are compared with DMPK-C cards and 903 cards, they are also excellent in terms of refrigerated storage stability.
[0148] When examining the above results, DMPK-A cards and B cards were treated with chemical agents, while DMPK-C cards and 903 cards were not treated with chemical agents (Am. J. Trop. Med. Hyg., 99 (2), 2018, pp. 256-265 or Bioanalysis, 2013, 5, 2613-30, etc.).
[0149] Therefore, it can be speculated that whether or not the chemical agent is used for treatment and its type will affect the refrigerated storage stability.
[0150] In addition, regarding the above-mentioned chemical agent, it is a free radical inhibitor (sodium dodecyl sulfate) in the DMPK-A card and a chaotropic agent (guanidine thiocyanate) in the DMPK-B card (Am. J. Trop. Med. Hyg., 99 (2), 2018, pp. 256-265 or Bioanalysis, 2013, 5, 2613-30, etc.).
[0151] <Example 3: Study on Optimization of Filter Paper from the Perspective of Storage Stability at Room Temperature>
[0152] For the filter paper to which the blood from the subject is added (i.e., the filter paper equivalent to the filter paper in step 1 described in the present invention), the optimal filter paper for quantifying NAD+ and NMN is explored when the filter paper to which the blood from the subject is added is stored at room temperature.
[0153] The specific experimental method is as follows.
[0154] [Experimental methods]
[0155] A portion of the blood-spotted filter paper prepared in Example 2 was sealed in a hygroscopic standard bag (hygroscopic Kun (registered trademark) / Maruto Sangyo Co., Ltd.) and stored at room temperature. After being stored at room temperature for 2 days, 1 week (7 days) or 2 weeks (15 days), the blood-spotted part was cut and recovered in a 2 mL microtube. After the same treatment as in Example 2, the measurement was performed by LC-MS / MS under the same conditions as in Example 2.
[0156] [Experimental results]
[0157] The above experimental results are shown in Tables 12 to 15.
[0158] [Table 12]
[0159]
[0160] [Table 13]
[0161]
[0162] [Table 14]
[0163]
[0164] [Table 15]
[0165]
[0166] As is clear from Table 12, regarding NAD+, the concentration of NAD+ after 2 days and 2 weeks of storage when using DMPK-A card was 71.6% and 51.6% of the initial value (0 day), respectively, showing good storage stability. In addition, as is clear from Table 13, the concentration of NAD+ after 2 days, 1 week, and 2 weeks of storage when using DMPK-B card was 82.0%, 87.2%, and 67.6% of the initial value (0 day), respectively, showing better room temperature storage stability compared to the case of using DMPK-A card.
[0167] On the other hand, it is clear from Table 14 that the NAD+ concentration after 2 days and 2 weeks of storage when using DMPK-C card is 55.9% and 50.2% of the initial value (0 day), respectively, and it is clear from Table 15 that the NAD+ concentration after 2 days and 2 weeks of storage when using 903 card is 66.2% and 50.3% of the initial value (0 day), respectively. From these results, it can be seen that, with respect to NAD+, DMPK-A card and B card are superior in terms of room temperature storage stability when compared with DMPK-C card and 903 card.
[0168] In addition, regarding NMN, it is clear from the above Tables 12 and 13 that although the numerical values fluctuate slightly, the storage stability is not significantly impaired when DMPK-A and B cards are used, and NMN can be quantified.
[0169] On the other hand, it is clear from Table 14 that the concentration of NMN after 2 days and 2 weeks of storage when using DMPK-C cards cannot be quantified. In addition, it is clear from Table 15 that the concentration of NMN after 2 days of storage when using 903 cards is 79.8% of the initial value (0 days), but the concentration of NMN after 2 weeks of storage cannot be quantified. From this result, it can be seen that regarding NMN, if DMPK-A cards and B cards are compared with DMPK-C cards and 903 cards, they are excellent in terms of room temperature storage stability.
[0170] When the above results are examined, similarly to Example 2, it can be inferred that the cause is whether or not the treatment is performed using a chemical agent and the type of chemical agent.
[0171] <Example 4: Study on Optimization of Filter Paper from the Perspective of Extraction Efficiency>
[0172] For the filter paper to which the blood from the subject is added (i.e., the filter paper equivalent to the filter paper in step 1 described in the present invention), the optimal filter paper for quantifying NAD+ and NMN is explored from the perspective of the efficiency of extracting NAD+ and NMN from the filter paper to which the blood from the subject is added.
[0173] The specific experimental method is as follows.
[0174] [Experimental methods]
[0175] The extraction efficiency of NAD+ and NMN was evaluated based on the presence or absence of filter paper. The preparation method of the sample without filter paper was the same as that in Example 2.
[0176] On the other hand, the method for preparing the sample with filter paper was also the same as that of Example 2. That is, 5 μL of blood was spotted onto 4 types of filter paper (Whatman FTA DMPK-ACard / GE healthcare, QIAcard FTA DMPK-BCard / QIAGEN, QIAcard FTA DMPK-C Card / QIAGEN, Whatman 903 protein saver card / Cytiva), and then various treatments were performed in the same manner as in Example 2. The samples were then measured by LC-MS / MS under the same conditions as in Example 2 without refrigeration or room temperature storage for a predetermined period of time as in Examples 2 and 3.
[0177] [Experimental results]
[0178] The above experimental results are shown in Tables 16 and 17.
[0179] [Table 16]
[0180]
[0181] [Table 17]
[0182]
[0183] It is clear from Table 16 above that regarding NAD+, when using DMPK-A and B cards, the efficiency of extracting NAD+ from filter paper (calculated based on the concentration value without filter paper) was 95.1% and 90.9% respectively, showing good extraction efficiency.
[0184] On the other hand, it is clear from Table 17 that the efficiency of extracting NAD+ from the filter paper when using the DMPK-C card and the 903 card was 72.9% and 77.2%, respectively. From this result, it can be seen that, with respect to NAD+, the DMPK-A and B cards are superior in extraction efficiency when compared with the DMPK-C card and the 903 card.
[0185] In addition, regarding NMN, it is clear from the above Table 16 that when using DMPK-A and B cards, the efficiency of extracting NMN from filter paper (calculated based on the concentration value without filter paper) is 125.6% and 87.7%, respectively, showing good extraction efficiency.
[0186] On the other hand, it is clear from Table 17 that the extraction efficiency of the filter paper when using the DMPK-C card and the 903 card is 87.9% and 73.2%, respectively. According to this result, it can be seen that, regarding NMN, when the DMPK-A and B cards are compared with the DMPK-C card and the 903 card, they are superior in terms of extraction efficiency.
[0187] If the results of the above-mentioned embodiments 2 to 4 are further reviewed, the DBS method of the present invention is usually mostly implemented with the premise of including self-blood collection. Therefore, in terms of physics or time, there are many cases in which the process of adding blood from the subject to the filter paper and the process of quantifying the quantitative object substance contained in the filter paper are carried out in different stages. More specifically, the process of adding blood to the filter paper is implemented by the subject (such as a person) himself at home. Thereafter, the filter paper is transported to an institution (inspection institution, medical institution, etc.) with a mass spectrometer such as LC-MS / MS, in which the process of quantifying the quantitative object substance is implemented. Therefore, when implementing the DBS method, it is necessary to store the filter paper at room temperature or under refrigeration for a specified time (such as several days to about 1 month). In addition, when storing the filter paper, it is also necessary to prevent the decomposition of the quantitative object substance. Therefore, for the filter paper used in the DBS method, it is required that the storage stability of the quantitative object substance is excellent.
[0188] According to Examples 2 to 4, it can be said that the DMPK-A card and the DMPK-B card (i.e., the filter paper in step 1 of the present invention) can satisfy the above properties. That is, it is found that they are the most suitable for the quantitative method of NAD+ and NMN using the DBS method.
[0189] <Example 5: Study on the Storage Stability of the Extracted Solution>
[0190] The storage stability of the solvent (extracting solution) after the filter paper to which the blood from the subject was added was examined (hereinafter, sometimes abbreviated as a post-extraction solution).
[0191] The specific methods are as follows.
[0192] [Experimental methods]
[0193] A portion of the blood extract solution (100% water) and a portion of the solution for LC-MS / MS measurement (water containing 67% acetonitrile) after the filter paper obtained in Example 2 was stored (refrigerated for 15 days) were frozen and stored separately. After 71 days of frozen storage, acetonitrile was added twice as much as the amount of the former, mixed and centrifuged (24250×g, 10 minutes, 4°C), and the supernatant was subjected to the same conditions as in Example 2. For the latter, the solution after storage was centrifuged (24250×g, 10 minutes, 4°C), and the supernatant was subjected to the same conditions as in Example 2 and measured by LC-MS / MS.
[0194] [Experimental results]
[0195] The above experimental results are shown in Tables 18 to 21.
[0196] [Table 18]
[0197]
[0198] [Table 19]
[0199]
[0200] [Table 20]
[0201]
[0202] [Table 21]
[0203]
[0204] It is clear from Tables 18 and 19 that the storage stability of NAD+ for the extracts of each filter paper when stored in the state of the extract (100% water) is: 93.1% for the DMPK-B card, showing good storage stability. The extracts of DMPK-A, C and 903 cards are 145.8%, 200.6% and 266.3%, respectively, all showing significantly higher values than the initial values.
[0205] On the other hand, it is clear from Tables 20 and 21 that for the extracts of each filter paper, the storage stability of NAD+ when stored in the form of a solution with acetonitrile added to the extract is: 89.6%, 73.6% and 92.1% for DMPK-A, C and 903 cal, respectively, which is an improvement compared to the values in the state of the extract (100% water).
[0206] When considering the above results, it can be inferred that, regarding the DMPK-B card, since NAD+ is fully inactivated at the time of extraction, it is stable even in a 100% water state. On the other hand, regarding the DMPK-A, C, and 903 cards, NAD+ is not fully inactivated during extraction, and when stored in a 100% water state, there is a tendency to fluctuate upward compared to the initial value due to the progress of the enzyme reaction, etc., so it can be inferred that they are inactivated by adding acetonitrile, thereby being stable in storage.
[0207] According to the above results, it can be known that in the art, a prescribed amount of organic solvents such as acetonitrile is added to achieve storage stabilization of the solution after extraction. However, when using the DMPK-B card, it is not necessary to add an organic solvent such as acetonitrile to the solution after extraction, and as a result, the quantification of NAD+ can be performed more simply. In addition, if further comments are made on this point, it is not necessary to add a prescribed amount of organic solvents such as acetonitrile, so the following possibility is revealed: when quantifying NAD+ in the solution after extraction, in addition to methods using mass spectrometers such as LC-MS / MS, a simpler method can be used compared with methods using mass spectrometers such as colorimetry and fluorescence. This is because: if a prescribed amount of organic solvents such as acetonitrile is added, it is impossible to implement colorimetry and fluorescence from the sensitivity caused by the dilution of the concentration of NAD+ in the sample and the compatibility of reagents such as surfactants contained in the kits of acetonitrile and colorimetry and fluorescence.
[0208] Industrial Applicability
[0209] The present invention can be used in industries related to methods for quantifying NAD+ or NMN and other NAD+ precursors using the DBS method.
Claims
1. A method for quantifying nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN) as a test subject, comprising the following steps 1 and 2: (Step 1) a step of bringing filter paper to which the blood from the subject is added and which is impregnated with a free radical inhibitor or a chaotropic agent into contact with a solvent; and (Step 2) A step 2 of quantifying the nicotinamide adenine dinucleotide (NAD+) or nicotinamide mononucleotide (NMN) in the solvent obtained in the step 1. 2 . The method according to claim 1 , which is a method for quantifying nicotinamide adenine dinucleotide (NAD+).
3. The method according to claim 1 or 2, in, The filter paper is impregnated with a chaotropic agent.
4. The method according to claim 1 or 2, in, The free radical inhibitor comprises a surfactant.
5. The method according to claim 4, in, The surfactant is an anionic surfactant.
6. The method according to claim 5, in, The anionic surfactant is sodium lauryl sulfate.
7. The method according to claim 3, in, The chaotropic agent comprises a guanidine salt.
8. The method according to claim 7, in, The guanidine salt is guanidine thiocyanate.
9. The method according to any one of claims 1 to 8, in, The filter paper is formed from cellulose.
10. The method according to any one of claims 1 to 9, in, The solvent is water and / or acetonitrile.
11. The method according to claim 10, in, The solvent is water.
12. The method according to any one of claims 1 to 11, in, The quantification in the step 2 is performed by a method using a mass spectrometer or a colorimetric method.
13. A kit for carrying out the method according to any one of claims 1 to 12, comprising a blood collection device and filter paper impregnated with a free radical inhibitor or a chaotropic agent.
14. Filter paper used for carrying out the method according to any one of claims 1 to 12, and impregnated with a free radical inhibitor or a chaotropic agent.
Citation Information
Cited By
Compound stabilizer for blood sampling card
CN121087139A
Composite stabilizer for blood collection card
CN121087139B
